Complement cash

Why HBM co-led True North’s $45M series D round

True North Therapeutics Inc.’s first clinical data for lead molecule TNT009 convinced new investor HBM Healthcare Investments to co-lead this month’s $45 million series D round.

The other co-leads were new investor Redmile Group and

Read the full 342 word article

User Sign In